Latest Camptothecin Stories
CAMBRIDGE, Mass., March 25, 2011 /PRNewswire/ -- Mersana Therapeutics today announced the initiation of a Phase 1b extension study with its lead cancer product, XMT-1001, a novel DNA topoisomerase I inhibitor based on the company's FleximerÂ® polymer conjugate platform, in second-line gastric cancer and second-/third-line non-small cell lung cancer.
CAMBRIDGE, Mass., April 20 /PRNewswire/ -- Mersana Therapeutics, a platform-based cancer therapeutics company, announced today positive preclinical pharmacokinetic data for its lead development candidate, XMT-1001, which is currently in a Phase 1 clinical trial in patients with advanced solid tumors.
CAMBRIDGE, Mass., Nov.
Cell cycle checkpoints act like molecular tripwires for damaged cells. Leave the tripwire in place for too long, however, and cancer cells will press on regardless, making them resistant to certain types of chemotherapy, according to researchers at the Salk Institute for Biological Studies.
BRIDGEWATER, N.J. and PARIS, Dec. 22 /PRNewswire/ -- Drais Pharmaceuticals, Inc. and Diatos S.A. today announced that they have entered into a global agreement to develop and commercialize DTS-108 for the treatment of solid tumors.
Taiwan Liposome and Aptuit Consulting, a subsidiary of Aptuit, has announced that Taiwan Liposome's Lipotecan cleared review by the FDA following the filing of an investigational new drug application, the first anticancer drug from Taiwan to achieve this milestone.
UC Davis Cancer Center researchers have discovered a genetic switch that causes cancer cells to become more sensitive to a drug administered to enhance radiation therapy effectiveness. The switch does not make the drug more toxic.
- Having no light.
- Of or relating to the region of a body of water that is not reached by sunlight and in which photosynthesis is unable to occur.